407 related articles for article (PubMed ID: 32804918)
1. Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
Zhu DS; Dong JY; Xu YY; Zhang XT; Fu SB; Liu W
Med Sci Monit; 2020 Aug; 26():e927106. PubMed ID: 32804918
[TBL] [Abstract][Full Text] [Related]
2. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
Gen Y; Yasui K; Nishikawa T; Yoshikawa T
Cancer Sci; 2013 Jul; 104(7):810-6. PubMed ID: 23510069
[TBL] [Abstract][Full Text] [Related]
3. Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer.
Du W; Gao A; Herman JG; Wang L; Zhang L; Jiao S; Guo M
Cancer Sci; 2021 Jul; 112(7):2870-2883. PubMed ID: 33931924
[TBL] [Abstract][Full Text] [Related]
4. Thioridazine Sensitizes Esophageal Carcinoma Cell Lines to Radiotherapy-Induced Apoptosis In Vitro and In Vivo.
Li H; Juan L; Xia L; Wang Y; Bao Y; Sun G
Med Sci Monit; 2016 Jul; 22():2624-34. PubMed ID: 27453171
[TBL] [Abstract][Full Text] [Related]
5. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
[TBL] [Abstract][Full Text] [Related]
6. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
7. The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis.
Basu D; Salgado CM; Bauer B; Khakoo Y; Patel JR; Hoehl RM; Bertolini DM; Zabec J; Brzozowski MR; Reyes-Múgica M
Cancer Genomics Proteomics; 2018; 15(4):239-248. PubMed ID: 29976629
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.
Lu Z; Zhang Y; Xu Y; Wei H; Zhao W; Wang P; Li Y; Hou G
Mol Biol Rep; 2022 Jan; 49(1):451-461. PubMed ID: 34731371
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of DEAD-box 51 inhibits tumor growth of esophageal squamous cell carcinoma
Hu DX; Sun QF; Xu L; Lu HD; Zhang F; Li ZM; Zhang MY
World J Gastroenterol; 2022 Jan; 28(4):464-478. PubMed ID: 35125830
[TBL] [Abstract][Full Text] [Related]
11. CircPDE5A-encoded novel regulator of the PI3K/AKT pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1.
Lei K; Liang R; Liang J; Lu N; Huang J; Xu K; Tan B; Wang K; Liang Y; Wang W; Lin H; Wang M
J Exp Clin Cancer Res; 2024 Apr; 43(1):124. PubMed ID: 38658954
[TBL] [Abstract][Full Text] [Related]
12. PLCD3 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/P21 signaling.
Wang M; Gao M; Chen Y; Wu J; Wang X; Shu Y
BMC Cancer; 2023 Sep; 23(1):921. PubMed ID: 37773107
[TBL] [Abstract][Full Text] [Related]
13. MiR-214 promotes cell meastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling pathway.
Guanen Q; Junjie S; Baolin W; Chaoyang W; Yajuan Y; Jing L; Junpeng L; Gaili N; Zhongping W; Jun W
Biomed Pharmacother; 2018 Sep; 105():350-361. PubMed ID: 29864623
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
15. XPD inhibits cell growth and invasion and enhances chemosensitivity in esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathway.
Jian J; Li S; Liu LZ; Zhen L; Yao L; Gan LH; Huang YQ; Fang N
Int J Mol Med; 2020 Jul; 46(1):201-210. PubMed ID: 32377720
[TBL] [Abstract][Full Text] [Related]
16. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling.
Cao YY; Yu J; Liu TT; Yang KX; Yang LY; Chen Q; Shi F; Hao JJ; Cai Y; Wang MR; Lu WH; Zhang Y
Cell Death Dis; 2018 Jan; 9(2):17. PubMed ID: 29339720
[TBL] [Abstract][Full Text] [Related]
17. Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.
Cao J; Lv W; Wang L; Xu J; Yuan P; Huang S; He Z; Hu J
Cell Death Dis; 2018 Jul; 9(8):817. PubMed ID: 30050135
[TBL] [Abstract][Full Text] [Related]
18. OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma.
Peng KZ; Ke Y; Zhao Q; Tian F; Liu HM; Hou G; Lu Z
Biochem Pharmacol; 2017 Sep; 140():16-27. PubMed ID: 28539264
[TBL] [Abstract][Full Text] [Related]
19. RUNX2 Plays An Oncogenic Role in Esophageal Carcinoma by Activating the PI3K/AKT and ERK Signaling Pathways.
Lu H; Jiang T; Ren K; Li ZL; Ren J; Wu G; Han X
Cell Physiol Biochem; 2018; 49(1):217-225. PubMed ID: 30138923
[TBL] [Abstract][Full Text] [Related]
20. Effects of bufalin on the mTOR/p70S6K pathway and apoptosis in esophageal squamous cell carcinoma in nude mice.
Liu Y; Wang X; Jia Y; Liu Y
Int J Mol Med; 2017 Aug; 40(2):357-366. PubMed ID: 28656204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
